BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BC Extra | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications. The announcement by Adaptimmune...
BioCentury | Aug 22, 2019
Emerging Company Profile

Tscan: Tracking down novel T cell targets

Tscan is screening TCRs against a genome-wide library of antigens to systematically identify novel cancer targets for T cell therapies that avoid off-target toxicities. "Most targets have been discovered in a one-off fashion, notably by...
BC Extra | Aug 2, 2019
Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

AB Sciences drops masitinib for melanoma  AB Science S.A. (Euronext:AB) halted development of masitinib for metastatic melanoma despite reporting that the product led to a 33.3% overall response rate (ORR), the primary endpoint in the...
BC Extra | May 9, 2019
Company News

bluebird to rollout Zynteglo starting in Germany next half

bluebird expects to launch β-thalassemia gene therapy Zynteglo in Germany next half, followed by launches in Italy, France and the U.K. in 2020. In March, EMA's CHMP recommended conditional approval of Zynteglo to treat transfusion-dependent...
BC Innovations | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BioCentury | Dec 15, 2018
Product Development

Extending Immunocore’s runway

The $100 million upfront payment from Immunocore Ltd.’s most recent deal with Roche's Genentech Inc. unit gives it enough cash to read out pivotal data from lead program IMCgp100, a catalyst that could help justify...
BC Week In Review | Nov 30, 2018
Company News

Immunocore, Genentech team up to bring soluble TCR therapy into clinic

Despite losing at least five key executives this year, Immunocore Ltd. (Abingdon, U.K.) has teamed up with Genentech Inc. to advance the first soluble TCR-based therapy from their existing deal into clinical testing for solid...
BC Extra | Nov 19, 2018
Company News

Immunocore, Genentech team up to bring soluble TCR therapy into clinic

Despite losing at least five key executives this year, Immunocore Ltd. (Abingdon, U.K.) has teamed up with Genentech Inc. to advance the first soluble TCR-based therapy from their existing deal into clinical testing for solid...
BC Week In Review | Oct 26, 2018
Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the company's MAGE-A10 and MAGE-A4 SPEAR T cell therapies...
Items per page:
1 - 10 of 18